Skip to content

Implantation of an auditory brainstem implant for the treatment of incapacitating unilateral tinnitus

Implantation of an auditory brainstem implant for the treatment of incapacitating unilateral tinnitus - ABI for tinnitus

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON47290
Enrollment
10
Registered
2016-06-13
Start date
2016-07-28
Completion date
Unknown
Last updated
2024-10-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

tinnitus

Interventions

All study participants receive an ABI, which will be neurosurgically implanted. The ABI will be switched on 6 weeks after implantation. The surgery and post-surgery follow-up and switch-on procedure

Sponsors

Universitair Medisch Centrum Groningen
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Unilateral tinnitus - Severely invalidating tinnitus - Men or women, age >18yr - Tinnitus that is present >1 years and was stable during the last year - Tinnitus that is nonresponsive to indicated conventional existing treatments (hearing aids and cognitive behavioral therapy. If a psychologist has indicated that CBT may ameliorate tinnitus complaints, the patient should have tried CBT for long enough time to reasonably argue that these treatments were not successful. This is the same for hearing aids. - Ipsilateral ear: pure tone audiometry (PTA) thresholds >=40dB and

Exclusion criteria

Exclusion criteria: - Psychiatric pathology and/or an unstable psychological situation as declared by a psychiatrist - Unrealistic expectations as declared by the investigator and/or psychiatrist - Life expectancy II - Pregnancy - Anatomic abnormalities that would prevent appropriate placement of the stimulator housing in the bone of the skull - Anatomical abnormalities or surgical complications which might prevent placement of the ABI Active Electrode Array - If the individual is known to be intolerant of the materials used in the implant (medical grade silicone, platinum, iridium and parylene c)

Design outcomes

Primary

MeasureTime frame
The primary outcome is change in the Tinnitus Functioning Index (TFI). The endpoint is set at 1 year after implantation. Follow up will take place until 5 years after implantation.

Secondary

MeasureTime frame
• Safety: changes in hearing as measured by pure tone audiometry (PTA) and speech discrimination tests from baseline to follow up; changes in vestibular function as measured by vestibular tests between baseline and 3 months after initial stimulation with the ABI. • Change in TFI from 12 months to 5 years of follow up (long term effect). • Change in VAS (visual analogue scale)-scores (tinnitus loudness, tinnitus annoyance) from baseline to follow up. • Change in HADS-scores (Hospital Anxiety and Depression Scale) from baseline to follow up. • Change is THI-scores (Tinnitus Handicap Index) from baseline to follow up. • Tinnitus matching from baseline to follow up.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)